Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Apply
AGEN2373, Balstilimab, GVAX
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step